Keros Therapeutics, INC 8-K filings

Keros Therapeutics provided an update on its investigational therapies, rinvatercept for neuromuscular disorders and elritercept for myelodysplastic syndromes, detailing clinical trial progress and preclinical findings.

Keros Therapeutics announced its second quarter 2026 financial results, highlighting a reduced net loss and the initiation of a Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy patients.

Keros Therapeutics announced it will receive a $20 million development milestone payment from Takeda following the first patient dosing in the Phase 3 ELRiSE MDS clinical trial for elritercept.

Keros Therapeutics announced the resignation of CFO Keith Regnante, effective August 3, 2026, with Corporate Controller Annita Tanini stepping in as interim principal financial and accounting officer.

Keros Therapeutics has appointed Dr. Anne Prener, a veteran biopharmaceutical executive, to its Board of Directors effective July 1, 2026.

Keros Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Keros Therapeutics announced its CEO will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.

Keros Therapeutics announced its first quarter 2026 financial results, highlighting pipeline advancements and a strategic shift in R&D expenses.

Keros Therapeutics provides a corporate presentation detailing progress on rinvatercept in DMD and ALS, and updates on the elritercept global licensing agreement with Takeda Pharmaceuticals.

Keros Therapeutics announced a significant financial turnaround in 2025 with net income, driven by a Takeda license agreement, and outlined key clinical trial advancements for rinvatercept.

Keros Therapeutics announced the appointment of Charles Newton to its Board of Directors, bringing extensive healthcare finance and capital markets expertise, while Dr. Carl Gordon steps down.

Keros Therapeutics, Inc. furnished an updated corporate presentation to the SEC, highlighting its clinical-stage pipeline and strategic focus on TGF-beta superfamily signaling.

Keros Therapeutics reported a significantly reduced net loss in Q3 2025, driven by Takeda partnership revenue and pipeline advancements.

Keros Therapeutics announced a $375 million capital return program, including share repurchases from ADAR1 and Pontifax, and a subsequent tender offer, alongside board resignations.

Keros Therapeutics presented additional positive clinical data from its Phase 1 trial of KER-065, highlighting robust bone anabolic activity and potential for Duchenne muscular dystrophy.

Keros Therapeutics announced its CEO, Jasbir S. Seehra, Ph.D., will present at the 2025 Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference.

Keros Therapeutics announced that the U.S. FDA granted Orphan Drug designation for its investigational therapy KER-065 for the treatment of Duchenne muscular dystrophy.

Keros Therapeutics announced a strategic realignment to prioritize its KER-065 clinical program, discontinuing cibotercept development, and implementing Board and leadership transitions.

Keros Therapeutics reported a reduced net loss in Q2 2025, completed a strategic review, and plans to return $375 million to stockholders.

A biopharmaceutical company announced the dosing of the first patient in a pivotal Phase 3 clinical trial, triggering a $10 million milestone payment from its global licensing partner.

Keros Therapeutics, Inc. announced the voluntary resignation of its Chief Medical Officer, Dr. Yung H. Chyung, effective August 1, 2025, as he pursues other opportunities.

Keros Therapeutics, Inc. announced the conclusion of its strategic review, deciding to return $375 million in excess capital to stockholders while continuing the development of its lead product candidate, KER-065, for neuromuscular diseases.

Keros Therapeutics announced that its Chair and CEO, Jasbir Seehra, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025.

Keros Therapeutics, Inc. has announced the discontinuation of its cibotercept program for pulmonary arterial hypertension (PAH) following disappointing Phase 2 trial results and a significant corporate restructuring involving a 45% workforce reduction, while continuing its strategic alternatives review.

Keros Therapeutics' Chair and CEO, Jasbir S. Seehra, will participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference on May 13, 2025.

Keros Therapeutics announces a significant increase in net income for Q1 2025, driven by revenue from a license agreement with Takeda Pharmaceuticals, while also advancing its clinical pipeline.

Keros Therapeutics and Pontifax agree on director nominations for the 2025 Annual Meeting and standstill provisions.

Keros Therapeutics announces a strategic review to maximize stockholder value and adopts a limited-duration stockholder rights plan in response to significant stock accumulations.

Keros Therapeutics reports successful Phase 1 trial results for KER-065, meeting key safety, tolerability, pharmacokinetic, and pharmacodynamic objectives, supporting its potential for treating Duchenne muscular dystrophy (DMD) and other neuromuscular conditions.

Keros Therapeutics' board approved and adopted amended and restated bylaws to update corporate governance matters, effective immediately on March 5, 2025.